A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Tavaborole (Primary)
  • Indications Onychomycosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Anacor Pharmaceuticals
  • Most Recent Events

    • 08 Jul 2014 Results published in an Anacor Pharmaceuticals media release.
    • 08 Jul 2014 Primary endpoint 'Complete cure' has been met according to an Anacor Pharmaceuticals media release.
    • 08 Jul 2014 According to an Anacor Pharmaceuticals media release, the US FDA has approved tavaborole for the topical treatment of onychomycosis of the toenails on the basis of results from this an another trial (see CT profile 244674).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top